Bavarian Nordic stock jumps 16% on EMA mpox vaccine update

Bavarian Nordic (OTCPK:BVNKF) (OTCPK:BVNRY) shares jumped 16% Friday after the Danish vaccine developer said it has submitted data to the European Medicines Agency to support approval of its mpox/smallpox vaccine MVA-BN for adolescents aged 12 to 17.

The vaccine is currently approved by the EMA and FDA for people aged 18 or older. The FDA granted Emergency Use Authorization for use in adolescents in 2022 during a global outbreak of mpox.

MVA-BN is marketed as Jynneos in the U.S. and Switzerland, as Imvamune in Canada, and as Imvanex in the Europe and U.K. Mpox is also known as monkeypox.

Bavarian Nordic said the vaccine could receive EMA authorization for adolescents in Q4. The company is also preparing to initiate a clinical trial to evaluate the vaccine in children aged two to 12 years, according to a statement.

The World Health Organization declared mpox a global public health emergency earlier this week.

Tonix Pharmaceuticals (TNXP) and GeoVax Labs (GOVX) are also developing vaccines for mpox while Emergent BioSolutions (EBS) has an approved vaccine and treatment for smallpox, a related disease.

Earlier this week, shares of SIGA Technologies (SIGA) plunged on disappointing results from a study for its oral mpox treatment candidate.

Mpox test makers include Co-Diagnostics (CODX), Roche (OTCQX:RHHBY) (OTCQX:RHHBF), Abbott Laboratories (ABT) and Applied DNA Sciences (APDN)